
- Dossier preparation manuals
- <u>Q&A</u>
- <u>Create support request</u>
- IUCLID user community
- <u>Additional information</u>
- <u>Video tutorials</u>

SuperUser EPA/ORD/CCTE/SCDCD

- User Settings
- Logout
- Dashboard
- Substances
- 1,3-Cyclohexanedimethanamine, N1,N3...

Filtered aggr_1

c8636a42-2122-4587-b222-83066cf76852




Type at least 3 characters

REACH Complete 1,3-Cyclohexanedimethanamine, N1,N3-bis(2methylpropylidene)-

- 1 General information
 - 3
- 2 Classification & Labelling and PBT assessment
- 3 Manufacture, use and exposure
- 4 Physical and chemical properties
 - 24
- 5 Environmental fate and pathways 3
- 6 Ecotoxicological information
- 5
- 7 Toxicological information
 - 18
 - o 8c6c8320-84ed-41ae-8f05-3972e6b76ce9
 - 7.1 Toxicokinetics, metabolism and distribution

- 1
- 7.2 Acute Toxicity 3
- 7.3 Irritation / corrosion
- 47.4 Sensitisation
- 2
- 7.5 Repeated dose toxicity
- 7.6 Genetic toxicity
 - 3
- 7.7 Carcinogenicity
- 7.8 Toxicity to reproduction 1
 - 7.8.1 Toxicity to reproduction
 - 1
- flaf0b13-eeb8-4c14-8a4c-3644abbc53e5
- 7.8.2 Developmental toxicity /
 - teratogenicity
- 7.8.3 Toxicity to reproduction: other studies
- 7.9 Specific investigations
- 7.10 Exposure related observations in humans
- 7.11 Toxic effects on livestock and pets
- 7.12 Additional toxicological information
- 8 Analytical methods
- 9 Residues in food and feedingstuffs
- 10 Effectiveness against target organisms
- 11 Guidance on safe use
- 12 Literature search
- 13 Assessment reports
- 14 Information requirements
- Inherited templates

UUID flaf0b13-eeb8-4c14-8a4c-3644abbc53e5 🔲 Hide empty fields



Endpoint screening for reproductive / developmental toxicity

Type of information experimental study

| Robust study summary |
|--|
| Used for classification |
| Used for SDS |
| Study period |
| Reliability 1 (reliable without restriction) |
| Rationale for reliability incl. deficiencies |
| Data waiving |
| Justification for data waiving |
| Justification for type of information |
| Attached justification |
| # Attached justification Reason / purpose Actions |
| Cross-reference |
| # Reason / purpose for cross-reference Related information Remarks Actions |
| Data source |
| Reference |
| • study monort Ummonod 2011 2011 10 28 |

• study report | Unnamed | 2011 | 2011-10-28

Data access

Data protection claimed

Materials and methods

Test guideline

Qualifier Guideline Version / remarks Deviations Actions 1 Qualifier according to guideline Guideline OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test) Version / remarks Deviations no 2 Qualifier according to guideline Guideline other: Version / remarks Deviations no

Principles of method if other than guideline

GLP compliance yes (incl. QA statement)

Limit test

no

Justification for study design

Test material

Test material information

• Unnamed | Unnamed | Incorez 397 | Unnamed | (2-methylpropylidene)[(3-{[(2-methylpropylidene)amino]methyl}cyclohexyl)methyl]amine | EC 619-764-7 | 173904-11-5

Additional test material information

Specific details on test material used for the study

Specific details on test material used for the study (confidential)

| Test animals |
|---|
| Species rat |
| Strain other: |
| Details on species / strain selection |
| Sex male/female |
| Details on test animals or test system and environmental conditions |
| Administration / exposure |
| Route of administration oral: gavage |
| Type of inhalation exposure (if applicable) |
| Mass median aerodynamic diameter (MMAD) |
| Geometric standard deviation (GSD) |
| Remarks on MMAD |
| Vehicle |
| Details on exposure |
| Details on mating procedure |
| Analytical verification of doses or concentrations |
| Details on analytical verification of doses or concentrations |
| Duration of treatment / exposure |
| Frequency of treatment |

Doses / concentrations # Dose / conc. Remarks Actions No. of animals per sex per dose Control animals Details on study design Positive control Examinations Parental animals: Observations and examinations Oestrous cyclicity (parental animals) Sperm parameters (parental animals) Litter observations Postmortem examinations (parental animals) Postmortem examinations (offspring) Statistics Reproductive indices Offspring viability indices Any other information on materials and methods incl. tables **Results and discussion** Results: P0 (first parental generation) General toxicity (P0) Clinical signs Description (incidence and severity) Dermal irritation (if dermal study) Description (incidence and severity) Mortality Description (incidence) Body weight and weight changes Description (incidence and severity) Food consumption and compound intake (if feeding study)

| Food efficiency |
|---|
| Description (incidence and severity) |
| Water consumption and compound intake (if drinking water study) |
| Description (incidence and severity) |
| Ophthalmological findings |
| Description (incidence and severity) |
| Haematological findings |
| Description (incidence and severity) |
| Clinical biochemistry findings |
| Description (incidence and severity) |
| Endocrine findings |
| Description (incidence and severity) |
| Urinalysis findings |
| Description (incidence and severity) |
| Behaviour (functional findings) |
| Description (incidence and severity) |
| Immunological findings |
| Description (incidence and severity) |
| Organ weight findings including organ / body weight ratios |
| Description (incidence and severity) |
| Gross pathological findings |
| Description (incidence and severity) |
| Neuropathological findings |
| Description (incidence and severity) |
| Histopathological findings: non-neoplastic |
| Description (incidence and severity) |
| Histopathological findings: neoplastic |
| Description (incidence and severity) |
| Other effects |
| Description (incidence and severity) |
| Reproductive function / performance (P0) |
| Reproductive function: oestrous cycle |
| Description (incidence and severity) |
| Reproductive function: sperm measures |
| |

Description (incidence and severity)

Reproductive performance

Description (incidence and severity)

Details on results (P0)

Effect levels (P0)

Key result Dose descriptor Effect level Based on Sex Basis for effect level Remarks on result Actions 1 Key result Dose descriptor NOAEL Effect level 250 mg/kg bw/day (nominal) Based on test mat. Sex male/female Basis for effect level • other: Remarks on result 2 Key result Dose descriptor NOAEL Effect level 750 mg/kg bw/day (nominal) Based on test mat. Sex male/female

Basis for effect level

• other:

Remarks on result

Target system / organ toxicity (P0)

Key result Critical effects observed Lowest effective dose / conc. System Organ Treatment related Dose response relationship Relevant for humans Actions

Results: P1 (second parental generation)

General toxicity (P1)

Clinical signs

Description (incidence and severity)

Dermal irritation (if dermal study)

Description (incidence and severity)

Mortality

| Description (incidence) |
|---|
| Body weight and weight changes |
| Description (incidence and severity) |
| Food consumption and compound intake (if feeding study) |
| Description (incidence and severity) |
| Food efficiency |
| Description (incidence and severity) |
| Water consumption and compound intake (if drinking water study) |
| Description (incidence and severity) |
| Ophthalmological findings |
| Description (incidence and severity) |
| Haematological findings |
| Description (incidence and severity) |
| Clinical biochemistry findings |
| Description (incidence and severity) |
| Endocrine findings |
| Description (incidence and severity) |
| Urinalysis findings |
| Description (incidence and severity) |
| Behaviour (functional findings) |
| Description (incidence and severity) |
| Immunological findings |
| Description (incidence and severity) |
| Organ weight findings including organ / body weight ratios |
| Description (incidence and severity) |
| Gross pathological findings |
| Description (incidence and severity) |
| Neuropathological findings |
| Description (incidence and severity) |
| Histopathological findings: non-neoplastic |
| Description (incidence and severity) |
| Histopathological findings: neoplastic |
| Description (incidence and severity) |
| Other effects |
| |

| Description (incidence and severity) |
|--|
| Details on results |
| Reproductive function / performance (P1) |
| Reproductive function: oestrous cycle |
| Description (incidence and severity) |
| Reproductive function: sperm measures |
| Description (incidence and severity) |
| Reproductive performance |
| Description (incidence and severity) |
| Details on results (P1) |
| Effect levels (P1) |
| # Key result Dose descriptor Effect level Based on Sex Basis for effect level Remarks on result Actions |
| Target system / organ toxicity (P1) |
| # Key result Critical effects observed Lowest effective dose / conc. System Organ Treatment related Dose response relationship Relevant for humans Actions |
| Results: F1 generation |
| General toxicity (F1) |
| Clinical signs |
| Description (incidence and severity) |
| Dermal irritation (if dermal study) |
| Description (incidence and severity) |
| Mortality / viability |
| Description (incidence and severity) |
| Body weight and weight changes |
| Description (incidence and severity) |
| Food consumption and compound intake (if feeding study) |
| Description (incidence and severity) |
| Food efficiency |
| Description (incidence and severity) |
| Water consumption and compound intake (if drinking water study) |
| Description (incidence and severity) |

| Ophthalmological findings |
|--|
| Description (incidence and severity) |
| Haematological findings |
| Description (incidence and severity) |
| Clinical biochemistry findings |
| Description (incidence and severity) |
| Urinalysis findings |
| Description (incidence and severity) |
| Sexual maturation |
| Description (incidence and severity) |
| Anogenital distance (AGD) |
| Description (incidence and severity) |
| Nipple retention in male pups |
| Description (incidence and severity) |
| Organ weight findings including organ / body weight ratios |
| Description (incidence and severity) |
| Gross pathological findings |
| Description (incidence and severity) |
| Histopathological findings |
| Description (incidence and severity) |
| Other effects |
| Description (incidence and severity) |
| Developmental neurotoxicity (F1) |
| Behaviour (functional findings) |
| Description (incidence and severity) |
| Developmental immunotoxicity (F1) |
| Developmental immunotoxicity |
| Description (incidence and severity) |
| Details on results (F1) |
| Effect levels (F1) |

Key result Dose descriptor Generation Effect level Based on Sex Basis for effect level Remarks on result Actions 1

Dose descriptor NOAEL Generation F1 Effect level 750 mg/kg bw/day (nominal) Based on test mat. Sex male/female Basis for effect level • other: Remarks on result Target system / organ toxicity (F1) # Key result Critical effects observed Lowest effective dose / conc. System Organ Treatment related Dose response relationship Relevant for humans Actions **Results: F2 generation** General toxicity (F2) Clinical signs Description (incidence and severity) Dermal irritation (if dermal study) Description (incidence and severity) Mortality / viability Description (incidence and severity) Body weight and weight changes Description (incidence and severity) Food consumption and compound intake (if feeding study) Description (incidence and severity) Food efficiency Description (incidence and severity) Water consumption and compound intake (if drinking water study) Description (incidence and severity) Ophthalmological findings Description (incidence and severity) Haematological findings Description (incidence and severity) Clinical biochemistry findings Description (incidence and severity)

| Urinalysis findings |
|---|
| Description (incidence and severity) |
| Sexual maturation |
| Description (incidence and severity) |
| Anogenital distance (AGD) |
| Description (incidence and severity) |
| Nipple retention in male pups |
| Description (incidence and severity) |
| Organ weight findings including organ / body weight ratios |
| Description (incidence and severity) |
| Gross pathological findings |
| Description (incidence and severity) |
| Histopathological findings |
| Description (incidence and severity) |
| Other effects |
| Description (incidence and severity) |
| Developmental neurotoxicity (F2) |
| Behaviour (functional findings) |
| Description (incidence and severity) |
| Developmental immunotoxicity (F2) |
| Developmental immunotoxicity |
| Description (incidence and severity) |
| Details on results (F2) |
| Effect levels (F2) |
| # Key result Dose descriptor Generation Effect level Based on Sex Basis for effect level Remarks on result Actions |
| Target system / organ toxicity (F2) |
| # Kay manik Critical officets also mad Lawast affective dass / some System Orean Treatment related Dass regeneres relationship Delevant for |

Key result Critical effects observed Lowest effective dose / conc. System Organ Treatment related Dose response relationship Relevant for humans Actions

Overall reproductive toxicity

Key result Reproductive effects observed Lowest effective dose / conc. Treatment related Relation to other toxic effects Dose response relationship Relevant for humans Actions 1

Key result Reproductive effects observed not specified Lowest effective dose / conc. Treatment related Relation to other toxic effects Dose response relationship Relevant for humans

Any other information on results incl. tables

Overall remarks, attachments

Overall remarks

Attachments

Type Attached (confidential) document Attached (sanitised) documents for publication Remarks Actions

Illustration (picture/graph)

Applicant's summary and conclusion

Conclusions

Executive summary

TOP

- Dashboard
- Substances
- •
- Mixtures / Products
- Articles
- •

Categories

Toolbox

- Template
- Manage Reports

Inventory manager

- Contact
- Legal entity
- Sites
- Reference substance
- Test material
- Literature reference

User management

- User Settings
- Users
- Roles

- About
- Help